These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

838 related articles for article (PubMed ID: 32633235)

  • 21. SARS-CoV-2 perturbs the renin-angiotensin system and energy metabolism.
    Mori J; Oudit GY; Lopaschuk GD
    Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E43-E47. PubMed ID: 32469255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.
    Kai H; Kai M
    Hypertens Res; 2020 Jul; 43(7):648-654. PubMed ID: 32341442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renin-angiotensin-aldosterone system and COVID-19 infection.
    Alexandre J; Cracowski JL; Richard V; Bouhanick B;
    Ann Endocrinol (Paris); 2020 Jun; 81(2-3):63-67. PubMed ID: 32370986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?
    Aleksova A; Ferro F; Gagno G; Cappelletto C; Santon D; Rossi M; Ippolito G; Zumla A; Beltrami AP; Sinagra G
    J Intern Med; 2020 Oct; 288(4):410-421. PubMed ID: 32459372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments.
    Zolk O; Hafner S; Schmidt CQ;
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Jul; 393(7):1131-1135. PubMed ID: 32415494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic Hypothesis and Pharmacogenetics Side of Renin-Angiotensin-System in COVID-19.
    Gemmati D; Tisato V
    Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32899439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.
    Chung MK; Karnik S; Saef J; Bergmann C; Barnard J; Lederman MM; Tilton J; Cheng F; Harding CV; Young JB; Mehta N; Cameron SJ; McCrae KR; Schmaier AH; Smith JD; Kalra A; Gebreselassie SK; Thomas G; Hawkins ES; Svensson LG
    EBioMedicine; 2020 Aug; 58():102907. PubMed ID: 32771682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe?
    Shyh GI; Nawarskas JJ; Cheng-Lai A
    Cardiol Rev; 2020; 28(4):213-216. PubMed ID: 32496364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19.
    Hooper NM; Lambert DW; Turner AJ
    Clin Sci (Lond); 2020 Sep; 134(18):2489-2501. PubMed ID: 32990314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
    Kurdi A; Abutheraa N; Akil L; Godman B
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00666. PubMed ID: 33084232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic.
    Cure E; Cumhur Cure M
    Diabetes Metab Syndr; 2020; 14(4):349-350. PubMed ID: 32311651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19, Renin-Angiotensin System and Endothelial Dysfunction.
    Amraei R; Rahimi N
    Cells; 2020 Jul; 9(7):. PubMed ID: 32660065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities.
    Patoulias D; Katsimardou A; Stavropoulos K; Imprialos K; Kalogirou MS; Doumas M
    Curr Hypertens Rep; 2020 Sep; 22(11):90. PubMed ID: 32910274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hypertension, RAAS blockade and risk in COVID-19 patients].
    Spaak J; Kahan T
    Lakartidningen; 2020 Jun; 117():. PubMed ID: 32594472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.
    Sanchis-Gomar F; Lavie CJ; Perez-Quilis C; Henry BM; Lippi G
    Mayo Clin Proc; 2020 Jun; 95(6):1222-1230. PubMed ID: 32376099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Renin Angiotensin Axis, Angiotensin Converting Enzyme 2 and Coronavirus].
    Cano F; Gajardo M; Freundlich M
    Rev Chil Pediatr; 2020 Jun; 91(3):330-338. PubMed ID: 32730512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.
    Meng J; Xiao G; Zhang J; He X; Ou M; Bi J; Yang R; Di W; Wang Z; Li Z; Gao H; Liu L; Zhang G
    Emerg Microbes Infect; 2020 Dec; 9(1):757-760. PubMed ID: 32228222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis.
    Sadria M; Layton AT
    PLoS Comput Biol; 2020 Oct; 16(10):e1008235. PubMed ID: 33031368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension.
    Iaccarino G; Grassi G; Borghi C; Ferri C; Salvetti M; Volpe M;
    Hypertension; 2020 Aug; 76(2):366-372. PubMed ID: 32564693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.
    Pirola CJ; Sookoian S
    J Infect; 2020 Aug; 81(2):276-281. PubMed ID: 32474043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.